Not yet recruitingPhase 3NCT07554495

Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents

Studying Juvenile idiopathic arthritis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alfasigma S.p.A.
Principal Investigator
Catherine Vincent
Alfasigma S.p.A.
Intervention
Filgotinib(drug)
Enrollment
65 enrolled
Eligibility
8-18 years · All sexes
Timeline
2026 – 2027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07554495 on ClinicalTrials.gov

Other trials for Juvenile idiopathic arthritis

Additional recruiting or active studies for the same condition.

See all trials for Juvenile idiopathic arthritis →

← Back to all trials